XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Activities:      
Net income $ 6,201,000,000 $ 89,000,000 $ 5,364,000,000
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation expense 329,000,000 288,000,000 255,000,000
Amortization expense 1,721,000,000 1,192,000,000 1,149,000,000
Stock-based compensation expense 635,000,000 643,000,000 636,000,000
Deferred income taxes (116,000,000) (214,000,000) (2,098,000,000)
Net (gain) loss from equity securities 610,000,000 1,662,000,000 (1,241,000,000)
Acquired in-process research and development expenses 177,000,000 5,856,000,000 4,251,000,000
In-process research and development impairment 0 0 800,000,000
Write-downs for slow-moving and excess raw material and work in process inventory 121,000,000 40,000,000 547,000,000
Other 1,217,000,000 250,000,000 279,000,000
Changes in operating assets and liabilities:      
Accounts receivable, net 313,000,000 (1,171,000,000) (218,000,000)
Inventories 11,000,000 (195,000,000) (95,000,000)
Prepaid expenses and other (42,000,000) (214,000,000) (307,000,000)
Accounts payable (118,000,000) 80,000,000 (61,000,000)
Income taxes payable (364,000,000) (778,000,000) 272,000,000
Accrued liabilities 689,000,000 640,000,000 (389,000,000)
Net cash provided by operating activities 11,384,000,000 8,168,000,000 9,144,000,000
Investing Activities:      
Purchases of marketable debt securities (3,517,000,000) (20,315,000,000) (30,455,000,000)
Proceeds from sales of marketable debt securities 730,000,000 23,239,000,000 7,523,000,000
Proceeds from maturities of marketable debt securities 2,180,000,000 9,479,000,000 22,398,000,000
Acquisitions, including in-process research and development, net of cash acquired (1,402,000,000) (25,742,000,000) (4,251,000,000)
Purchases of equity securities (380,000,000) (455,000,000) (1,773,000,000)
Capital expenditures (579,000,000) (650,000,000) (825,000,000)
Other (163,000,000) (171,000,000) (434,000,000)
Net cash used in by investing activities (3,131,000,000) (14,615,000,000) (7,817,000,000)
Financing Activities:      
Proceeds from debt financing, net of issuance costs 0 8,184,000,000 0
Proceeds from issuances of common stock 169,000,000 256,000,000 209,000,000
Repurchases of common stock (546,000,000) (1,583,000,000) (1,749,000,000)
Repayments of debt and other obligations (4,750,000,000) (2,500,000,000) (2,750,000,000)
Payment of dividends (3,605,000,000) (3,449,000,000) (3,222,000,000)
Other (145,000,000) (138,000,000) (122,000,000)
Net cash (used in) provided by financing activities (8,877,000,000) 770,000,000 (7,634,000,000)
Effect of exchange rate changes on cash and cash equivalents (35,000,000) 43,000,000 (2,000,000)
Net change in cash and cash equivalents (659,000,000) (5,634,000,000) (6,309,000,000)
Cash and cash equivalents at beginning of period 5,997,000,000 11,631,000,000 17,940,000,000
Cash and cash equivalents at end of period 5,338,000,000 5,997,000,000 11,631,000,000
Supplemental disclosure of cash flow information:      
Interest paid, net of amounts capitalized 979,000,000 951,000,000 982,000,000
Income taxes paid $ 2,509,000,000 $ 2,639,000,000 $ 1,793,000,000